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Summary 
The present work was designed to evaluate the effects of functional suppression of complement 
regulatory proteins  in  vivo.  Male  Wistar  rats  were anesthetized with  Nembutal  and  were 
intravenously injected with 1 mg/kg of F(ab')2 or Fab fraction of either monoclonal antibody 
512, which inhibits the function of rat counterpart of mouse Crry/p65, or monoclonal antibody 
6D1, which inhibits the rat counterpart of CD59. Mean arterial pressure was continuously measured 
for 30 min. When 512 was injected, there was a biphasic change of mean arterial pressure, namely, 
the rapid increase immediately after the injection (~2 min, phase 1) and the subsequent fall and 
slow recovery ("o4-30 min, phase 2). These effects were completely abrogated by pretreatment 
of rats with cobra venom factor.  Pretreatment with carboxypeptidase inhibitor, which inhibits 
inactivation of anaphylatoxins C3a  and C5a,  induced enhanced reduction of blood pressure. 
Circulating leukocytes and platelets were rapidly decreased 5 rain after antibody injection and 
became normal by 2 h.  Hematocrit and erythrocyte count were continuously increased up to 
2  h  after injection,  suggesting  that  there was  hemoconcentration due to  increased vascular 
permeability. Immunofluorescence study revealed binding of antibody fragments and rat C3 along 
the capillaries  of lung, heart, and liver 5 min after injection. In contrast to 512, F(ab')2 fraction 
of 6D1,  though localized to the same areas and in similar amounts, had no significant effect 
on the parameters measured. These data suggest that the rat counterpart of mouse Crry/p65 
plays a vital role in vivo by preventing the activation of autologous complement on vascular 
endothelium. 
T 
he complement system plays important roles in the elimi- 
nation of foreign organisms. Complement proteins, when 
activated, become attached not only to the foreign bodies 
but also nearby host cells. Usually the host cells are protected 
from the complement-mediated injury by a number of com- 
plement regulatory proteins. C3 and C4 play central roles 
in the complement cascade and at least six regulatory pro- 
teins have been reported in human which bind C3b/C4b and 
regulate the complement activation (1). Among these regula- 
tory proteins,  decay accelerating factor (DAF) t  (2,  3)  and 
This work was presented  in part at the XVth International  Complement 
Workshop (26 September-1  October 1993, Kyoto,  Japan) and was published 
in abstract form (Mol. Immunol. Vol. 30, Suppl. 1:18). 
1 Abbreviations used in this paper: CPI, carboxypeptidase  inhibitor; CVF, 
cobra venom factor; DAF, decay accelerating factor; HKF20, 20-kD 
homologous restriction factor; MCP, membrane  cofactor  protein. 
membrane cofactor protein (MCP) (4-6) are cell membrane- 
associated proteins which are widely distributed not only on 
blood-borne cells but also on nonhematological cells such 
as endothelial cells and epithelial cells of various organs (7). 
Although the fact that deficiency of DAF and 20-kD homol- 
ogous restriction factor (HRF20, CD59) in the erythrocyte 
membrane results in the development of paroxysmal nocturnal 
hemoglobinuria (8-10) suggests the protective role of these 
proteins against complement-mediated erythrocyte lysis, the 
role of ceU membrane--associated complement regulatory pro- 
teins in other diseases is largely unknown. One of the main 
reasons for this is that functional analogues of DAF, MCP, 
and HtLF20 have not been well characterized in experimental 
animals until recently, and, therefore, it was impossible to 
study the function of these regulatory proteins in various dis- 
ease models. 
In mice, a DAF-like molecule (11) and another comple- 
ment regulatory protein,  Crry/p65  (12,  13), have been re- 
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and/or DAF. Until now no other molecule has been found 
that has functional and distributional similarities to human 
MCP and/or DAF. Crry/p65 transfected in human K562 cells 
inhibits neuraminidase  treatment-induced deposition of mouse 
C3 on cells, and soluble Crry/p65 inhibits deposition of mouse 
C3 on the zymozan partides (14). Thus, Crry/p65 is thought 
to be a major cell membrane-associated complement regula- 
tory protein of C3 convertase in mice. A rat mAb to Crry/p65 
has only recently been developed (15) and in vivo roles of 
this molecule are yet to be clarified. 
In rats,  Takizawa (16) recently developed a mouse mAb 
(designated  as  512,  IgG1  subclass)  against  rat  erythrocyte 
membrane which inhibited function of a rat cell membrane- 
associated  complement regulatory protein. Fab fragment of 
512 caused deposition of C3b on rat myeloma cells after treat- 
ment with rat serum. The antigen recognized by this mAb 
(512Ag) was considered a rat counterpart of mouse Crry/p65 
because of the similarities in function, distribution, and amino 
acid sequences (16,  17).  This has been verified by the high 
homology in base sequence of recently cloned 512Ag-cDNA 
with that of mouse Crry/p65 -cDNA (18). 512Ag is present 
in widespread organs and 512, when administered intrave- 
nously even in small amounts, clearly bound to these organs. 
Another mAb, 6D1, was recently developed against rat CD59 
by Hughes et al.  (19).  The rationale for the present study 
was to examine the in vivo effects of these reagents on the 
clinical  and  pathological  parameters.  Fab  or  F(ab')2  frag- 
ments of 512 and 6D1 bound to the capillary walls in various 
organs, but whereas 512 caused profound changes in blood 
pressure and other vascular and hematologic parameters in 
complement-replete animals,  6D1  had  little  effect.  These 
studies provide novel information on the in vivo roles of these 
two complement regulators. 
Materials and Methods 
Animals.  Male  Wistar rats weighing ,,o275 g and male BALB/c 
mice weighing ,,o20 g were purchased from Chubu Kagaku Shizai 
Company (Nagoya, Japan). They were allowed free access to food 
and water. 
mAbs.  Production  and characterization of 512 and 6D1 were 
described previously (16, 19). These mAbs belonged to the same 
subclass (IgG1) and showed similar binding distribution in rat organs 
(17). IgG1 fractions of these mAbs were prepared using protein 
A affinity  column chromatography (PharmaciaJapan, Tokyo,  Japan). 
The fractions were pooled, concentrated, and dialyzed against PBS. 
For the preparation of F(ab')2 fragments, 15 mg/ml of IgG1 frac- 
tion of each mAb was prepared in 1 M citrate buffer, pH 4.5, and 
0.5 mg/ml of pepsin was added. The mixture was incubated for 
8 h at 30~  and then the sample was diluted 1:4 in glycine buffer 
(1.45 M, pH 8.9). Undigested IgG1 and free Fc fragments were 
removed by protein A affinity column chromatography. The pass 
through fraction was concentrated and dialyzed against PBS and 
it was applied to a Sephadex G75 column. The first peak containing 
the F(ab')2 fragments  was collected, concentrated,  and dialyzed 
against PBS. Fab fragments  of 512 were prepared by incubating 
IgG1 fraction of 512 with immobilized papain for 5 h at 37~  fol- 
lowed by the absorption of Fc fragments and undigested IgG1 by 
a protein A affinity column chromatography. Size of IgG1, F(ab')2, 
and Fab fragments was analyzed by a SDS-PAGE. F(ab')2 fragment 
was not contaminated by IgG1, and Fab fragment did not contain 
IgG1 or F(ab')2 fragment.  When reactivity of these fragments 
with rabbit antibodies against mouse IgG-Fc by an Ouchterlony 
method, only native IgG1 showed positive result. Binding capacity 
of each fragment was tested by an indirect immunoftuorescence 
test on the normal rat lung as described below, and it was found 
that the reactivity was well preserved after enzyme digestion. 
Measurement of  Bacterial Endotoxin  in  the  Antibody  Frag- 
ments.  Contamination of bacterial endotoxin in the antibody frag- 
ments used in the present study was tested by an endotoxin detec- 
tion reagent (Pregel-M; Sekagaku  Kougyou Co. Ltd., Tokyo,  Japan) 
according to the manufacturer's direction. Bacterial LPS was used 
as a control.  Sensitivity of Pregel-M was  ~50 pg/ml (or 0.25 
EU/ml). 
Measurement of Serum Complement Activity.  500 #1 of freshly 
obtained whole blood was mixed with 100/~1 of 0.1 M ethylenedi- 
amine tetraacetate (EDTA-2Na). EDTA-plasma  was obtained by cen- 
trifugation of blood and was stored at  -70~  until use. For the 
determination of serum complement activity, CH50 was measured 
according to a manufacturer's direction using  sensitized SRBC 
(Ishizu Pharmaceutical Co.,  Osaka, Japan). 
Cobra Venom Factor.  Cobra venom factor (CVF) was routinely 
purified on DEAE sephadex from lyophilized cobra venom (Naja 
Naja; Sigma Chemical Co., St. Louis, MO) and was further purified 
by electrofocusing  to remove phospholipase A (,,o100-150  kD) (20). 
When 25 U of purified CVF was intravenously injected into a rat, 
the complement activity measured by CH50 became undetectable 
24 h after the injection. 
Measurement of Blood Pressure and Pulse Rate.  Animals were 
anesthetized by intraperitoneal injection with 50 mg/kg of pen- 
tobarbital sodium (Abbott Laboratories, North Chicago, IL). They 
were strapped in a supine position during surgery and experiments. 
A polystyrene catheter (SP25; Natsume Company, Tokyo, Japan) 
was placed into the left femoral artery approximately to the level 
of the aortic bifurcation, and was used for the measurement of ar- 
terial pressure and heart rate, which were monitored with trans- 
ducer for 30 min. Data were shown by percent change of mean 
arterial pressure and heart rate from the pretreatment value. Per- 
cent change of mean arterial pressure at the selected time point 
was calculated by the formula described below (see Hematological 
Study). 
Experimental Protocol..  Rats were stratified into seven groups. 
After stabilizing for a few minutes, rats were treated according to 
the following protocols. Group I rats were injected with 1.0 mg/kg 
of F(ab')2 fraction of 512 in 0.6 ml of saline. Group II rats were 
intravenously injected with 25 U of purified CVF 24 h before the 
administration of F(ab')2 fraction. Serum complement activity de- 
termined by CH50 was undetectable just before the antibody ad- 
ministration as described in group I rats. Group III rats were intra- 
venously injected with 1.0 mg/kg of Fab fraction of 512 instead 
of F(ab')2 fraction in order to examine the effects of valence of the 
antibody fraction. Group IV rats were intravenously injected with 
20 mg of carboxypeptidase inhibitor (CPI, DL-2-mercaptomethyl- 
3-guanidinoethyl thiopropanoic acid; Calbiochem Corp., LaJolla, 
CA) 2 h before administration of F(ab')z fraction of 512. CPI was 
reported to inhibit the inactivation of generated C5a and C3a by 
competitively  inhibiting the carboxypeptidase,  an inactivator of C3a 
and C5a that removes the terminal arginine residues of these vasoac- 
tive molecules (21). Group V rats were injected with 0.6 ml of 
saline from the tail vein for 5 s. These rats were used as controls. 
Group VI rats were intravenously injected with 25 U of purified 
CVF in order to see the effects on blood pressure of rapid activa- 
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of F(ab')2 fraction of 6D1 was injected instead of 512. Mean ar- 
terial pressure and heart rate were monitored in all rats for 30 min 
after administration of antibody fractions (groups I through V) 
or with CVF (group VI). In groups I, II, VI, and VII, separate 
sets of rats were killed 5 and 30 rain after the antibody injection 
for the immunofluorescence studies. These protocols are summa- 
rized in Table 1. 
Immunohistology.  Lung, heart,  and liver of all groups of rats 
except for group IV were studied by direct immunofluorescence 
test according to the previously described procedure (22, 23) 5 and 
30 min after injection. Briefly, tissues were snap-frozen in liquid 
nitrogen. 2-/zm-thick sections were cut by a cryostat and fixed in 
acetone at room temperature for 10 min. They were then incubated 
with fluorescein-conjugated goat antibodies against mouse IgG and 
rat C3 (Cappel Laboratories,  West Chester, PA). After washing 
in PBS, sections  were covered with 90%  glycerol containing p- 
phenylenediamine  (24) and were observed by an epifluorescence mi- 
croscope (Olympus Optical Co., Tokyo, Japan). 
In group I, V, and VII rats,  the number of leukocytes present 
in lung, heart, and liver was quantitated by direct immunofluores- 
cence method. Tissues were obtained at 5 min, 30 rain, 2 h, and 
24 h after antibody injection and they were processed  for direct 
immunofluorescence  study as described above. Frozen sections were 
stained  by  fluorescein-conjugated  mAb  against  rat  leukocyte 
common antigen  (OX-1;  Dainippon  Pharmaceutical Company, 
Osaka, Japan). In the case of lung, heart, and liver, the numbers 
of leukocyte common antigen-positive cells present in high power 
field (x 400) were counted under the epifluorescence  microscopy. 
An average number of positive cells from 10 different fields was 
calculated  in each rat. 
HematologicalStudy.  In rats of groups I, II, V, and VII, blood 
samples were obtained from the tail vein before, 5 min, 30 min, 
2 h, and 24 h after injection. Leukocytes,  platelets,  erythrocytes, 
and hematocrit were calculated by automatic blood cell counter. 
Data at each time point were expressed by percent change according 
to the following formula: 100  x  [(the value at the selected point 
-  preinjection value)/preinjection value]. 
Statistical Analysis.  Statistical  analysis was performed in non- 
parametric manners by the Mann-Whitney U-test for unpaired data, 
and by the Wilcoxon signed rank test for paired data. Significant 
difference between two groups was determined when the p value 
was <0.05  (5%). 
Results 
Endotoxin  in the Antibody Fragments.  All the stock solu- 
tions of antibody fragments of 512 and 6D1 (5 mg/ml each 
in endotoxin-free saline) were negative for endotoxin test by 
Pregel-M  reagent. 
Effects of 512 on Mean Arterial  Pressure and Pulse Rate in 
Rats.  When rats were injected with F(ab'z) fraction of 512 
(group I), there was an immediate increase in mean arterial 
pressure by "~30% after the injection ('~2 min, phase 1). The 
decrease of mean arterial pressure followed at 4 rain after the 
injection and thereafter. Blood pressure recovered slowly by 
30 min (phase 2). Administration of Fab (group III) showed 
quite similar results to those as seen in group I rats.  These 
data are depicted in Fig.  1 A.  The change in pulse rate in 
these rats was  within  5%  of the preinjection value. 
Effects of  Pretreatment with CVF and CPI.  When comple- 
ment was depleted by CVF before injection of 512  (group 
II), there was no decrease in mean arterial pressure. Rather 
it was  slightly increased  10 and  15 min after the antibody 
injection but there was no significant difference between group 
II and V  rats in  general.  When  rats were pretreated with 
CPI before injection of 512 (group IV), rats  showed severe 
respiratory distress 1-2 min after antibody administration and 
4 out of 8 rats died within several minutes. In the surviving 
rats, blood pressure was decreased by >50% 15 min after the 
administration of antibody fragment and the recovery of mean 
arterial pressure during phase 2 was seldom seen (Fig. 1 B). 
The degree of change in pulse rate was within  10% of the 
preinjection value in group II rats.  Similarly, the change of 
pulse rate in group IV rats was not significantly different from 
that  of group V  rats. 
Effects of Rapid Activation of Complements  by CVF on Ar- 
terial Pressure and Pulse Rate.  When rats were intravenously 
Table  1.  Protocols  for Immunofluorescence Studies 
Number  Pretreatment  Antibody fraction  Hematological  IF 
Group  of rats*  with  (antibody injected)  study~  study* 
I  5  None  F(ab')2 (512)  5  4 
II  5  CVF~  F(ab')2 (512)  5  5 
III  6  None  Fab (512)  Not tested  4 
IV  8  (4)11  CPI  ~  F(ab')2  (512)  Not tested  Not tested 
V  7  None  Saline  5  5 
VI  6  None  CVFS  Not tested  5 
VII  5  None  F(ab')z  (6D1)  5  5 
Protocol and number of rats for each experimental group are shown. 
* The number of rats used for blood pressure measurement is indicated. 
The number of rats used for hematological and immunofluorescence  studies is indicated. 
S Purified CVF was injected 24 h before antibody administration. 
IL The number in parentheses indicates number of rats which were dead within  several minutes after antibody administration. 
￿82  CPI was administered 2 h before antibody administration. See Materials and Methods and Results for details. 
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Percent change of mean arterial pressure. In A and C, asterisks 
show the significant change at the selected time point between control 
(group V) and each experimental group. (A) (*) Significant difference be- 
tween experimental  groups and group V. (B) (*) Significant difference 
between groups  IV and V. There was no significant difference between 
groups  V and II. (C) (*) Significant difference between groups V and 
VI and (@) between groups  V and VII. 
injected with 25 U  of purified CVF, serum complement ac- 
tivity determined by CHS0 became undetectable within 30 
min and this condition lasted at least for 48 h. Mean arterial 
pressure measured during this period (group VI) showed a 
decrease in the initial phase (2-5 rain after injection), and 
quick recovery by 10 min. These data are shown in Fig.  1 
C. Although pulse rate was significantly increased at 25 min 
after injection of CVF when compared with that of group 
V rats, overall change of pulse rate in group VI rats was not 
different from that in group V. 
Effects of 6D1 on Blood Pressure and Pulse Rate.  Adminis- 
tration of F(ab')2 fragment of 6D1 did not affect blood pres- 
sure (Fig.  1 C) or pulse rate. 
Organ  Binding of  Antibody  and  Complement.  When 
F(ab')2 or Fab fraction of 512 (1 mg/kg) was injected into 
rats via the tail vein (group I and III), binding of antibody 
to the lung, heart, and liver was observed 5 min after injec- 
tion.  In the lung and heart,  antibody was localized along 
the capillaries  (Fig.  2, A  and B).  In the liver,  the binding 
of antibody was observed along the sinusoidal space (Fig. 2 
C). Binding of rat C3 was also clearly observed in a similar 
area of these organs (Fig. 3, A-C). The binding of antibody 
and C3 became very weak in lung and liver 30 min after anti- 
body administration, whereas it was not significantly changed 
in heart. In complement-depleted rats (group II), there was 
binding of antibody as seen in rats of group I and III but 
deposition of C3 was not observed at all.  In rats of group 
VI, there was faint binding of C3 in the capillaries of heart 
tissue but  there was no significant binding of C3 in lung 
and liver 5 and 30 rain after CVF administration. Rats in- 
jected with 6D1 showed binding of antibody to lung, heart, 
and liver (Fig. 2, D-F) like in group I and III rats, but there 
was no C3 deposition in these organs (Fig. 3, D-F). These 
results are summarized in Table 2. 
Hematological Study.  Peripheral leukocytes and platelets 
were decreased by 60% compared with the preinjection value 
in group I rats 5 rain after antibody injection. Leukocyte count 
remained depressed 30 min after injection and returned to 
normal by 120 rain after injection (Fig. 4 A). Platelet count 
showed a similar change as seen for leukocytes (Fig.  4 B). 
Concentration of erythrocytes and hematocrit level increased 
continuously, reaching 30% above preinjection, 120 rain after 
the administration of F(ab')2 fraction of 512 (Fig.  4,  C and 
D). All these hematocrit parameters returned to the prein- 
jection values by 24 h after antibody injection in group I rats. 
Pretreatment of rats with CVF totally abrogated the effects 
512 on hematological parameters (group II). In rats injected 
with  F(ab')2  of 6D1  (group  VII),  there was  a  small but 
significant increase of leukocytes at 5 min and 24 h after in- 
jection (Fig. 4 A). There was also significant decrease of red 
blood cells and hematocrit at 24 h  after injection (Fig.  4, 
C and D). There was no significant change of platelet count 
throughout the experiment. 
Leukocyte Infiltration  in  Organs.  After  injection  with 
F(ab')2 fraction of 512 (group I), there was rapid accumula- 
tion of leukocytes in the organs studied. The number of leu- 
kocytes returned to the normal range 24 h after injection (Fig. 
5, A-C).  In contrast, rats injected with 6D1  (group VII) 
showed a mild increase of leukocyte accumulation only in 
the lung at 24 h after injection (Fig. 5 A). Rats injected with 
saline (group V) did not show increased leukocyte infiltra- 
tion in these organs. 
Discussion 
MCP and DAF have been shown to exist on the surface 
of vascular endothelium and it was suggested that the pres- 
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depicting the binding of"  antibody  fraction  in var- 
ious organs 5 min after administration of F(ab')2 
fraction of 512 (group I) or 6D1 (group VII). 
(A and D) Lung; (B and E) heart; (C and F) liver; 
(A-C) group I; (D-F) group VII. x400. 
ence of MCP and/or DAF protected these cells from the serum 
complement proteins (7). Data obtained in the present work 
revealed that 512 antigen (a rat counterpart of mouse Crry/p65) 
(16,  18) on the endothelial membrane played an important 
role at least in maintaining  the blood pressure and vascular 
permeability. When this molecule was functionally suppressed 
by a mAb, 512, complement activation occurred on the sur- 
face of vascular  endothelium.  Since  F(ab')2  and  Fab  frag- 
ments  of 512 were used in  this  study,  the events observed 
after antibody injection took place by the functional suppres- 
sion of 512Ag, but not by direct activation of complement 
through antigen-antibody interaction. It should also be noted 
that bacterial endotoxin was not present in the 512 antibody 
fragments used in this study. The fact that 6D1, a mAb which 
inhibits  function  of rat  CD59 and has  similar  distribution 
in vivo, had little influence on any parameter studied in this 
experiment  revealed  the importance  in vivo of a cell mem- 
brane molecule (rat Crry/p65) regulating complement acti- 
vation at C3 level.  Vascular  endothelial surface,  which does 
not activate complements under normal conditions, may be- 
come a slow activator of alternate pathway of complement 
when complement regulatory protein is inhibited by 512. After 
neutralization of rat CD59, the endothelium remains nonac- 
tivating and hence no significant effect is seen in vivo despite 
neutralization  of this important  inhibitor.  The mechanisms 
of rapid change in mean arterial pressure and increased vas- 
cular permeability after the antibody administration  can be 
explained as follows. First, generation of vasoactive fragments 
of complement cascade such as C5a and C3a lead to the change 
in blood pressure (25). This hypothesis is supported by the 
following findings. Pretreatment of CVF, which completely 
depleted the serum complement  activity,  totally abrogated 
the effects of 512. Furthermore,  CPI, which inhibits the in- 
activation of generated CSa and C3a (21), enhanced the shock- 
promoting effect of 512 and markedly inhibited the recovery 
of blood pressure in phase  2. 
Second,  activation of complement  system on the surface 
of vascular endothelium alters the endothelial function. Con- 
tinuous elevation of hematocrit  and RBC concentration  in 
group I rats indicated the increase of vascular permeability. 
This notion was deduced from the experiment studying the 
direct effects of CVF, which has a complement-activating effect 
similar to the C3 convertase and causes rapid consumption 
of complement  components in  the  fluid phase but  should 
not cause C3 deposition on the cell membranes. The fact that 
C3 deposition was only faintly observed in the capillaries  of 
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showing deposition of rat C3 in various organs 
of the same animals of Fig. 2. (A and D) Lung; 
(B and E) heart; (C and F) liver; (A-C) group 
I; (D--F) group VII.  x400. 
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the administration of F(ab')2  frac- 
tion of 512 (group I) in compar- 
ison with those of group V and 
group VII. Data are shown by per- 
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heart and not at all in the other organs in group VI rats sup- 
ports this notion. Thus, it could be easily imagined that there 
was rapid generation of C5a and C3a in the circulation but 
these could also be quickly inactivated by the carboxypepti- 
dase in the plasma and only transient fall of blood pressure 
resulted. In contrast, prolonged effects of 512 suggested that 
impairment of vascular endothelial cell function due to the 
activation of complement on the endothelial cell surface was 
rather slow but continuous since deposition of C3 was clearly 
observed in the vasculature of all organs  studied. 
Third, the rapid decrease and recovery of leukocytes and 
platelets in the circulating  blood suggested that they were 
transiently captured or stuck to the vascular endothelium of 
some organs. C3b deposited on the vascular endothelial sur- 
face induced by 512 injection might be a ligand for C3b 
receptor present on the surface of leukocytes. On the other 
hand, most blood cells express 512 Ag on their surface (17). 
Neutralization of 512Ag on leukocytes  might also render them 
complement activating, resulting in deposition  of comple- 
ment fragments, release of C3a and C5a, and consequent re- 
lease of other vasoactive substances from leukocytes attached 
in the vasculature. The outcome would be a cell-dependent 
increase  in vascular permeability (26). This hypothesis remains 
to be tested. 
Recently it has been shown that the complement system 
was activated during the endotoxin shock (27-29) and anti- 
bodies against C5a abolished the shock-promoting effects of 
endotoxins  (25). In turn, administration  of C5a in rabbits 
has been reported to induce endotoxin shocklike symptoms 
(30, 31). It is now widely accepted that complement system 
is deeply involved in the pathogenesis  of endotoxin shock 
(32). Although the relationship between the shock-promoting 
effects of endotoxins and the cell membrane-associated regu- 
lators of complement activation has never been studied, the 
present work clearly demonstrated that the functional sup- 
pression of complement regulatory proteins on the cell mem- 
branes leads to the profound hemodynamic changes. Although 
there has been no report describing the effects of cytokines 
on the expression of membrane inhibitors  of complements, 
it is interesting from the present results to study the rela- 
tionship between shock-promoting effects of endotoxins and 
the expression of these  molecules  on the endothelial  cell 
membrane. 
In humans,  vascular endothelial  cells express both DAF 
and MCP presumably to protect them from indiscriminate 
attack by autologous complement (3, 33). The reason why 
suppression of only one molecule (a rat analogue of mouse 
Crry/p65) induced dramatic changes in rats might be explained 
by a recent study showing that mouse Crry/p65 has both 
MCP and DAF activities. Takizawa et al. (16) demonstrated 
that 512Ag is a rat counterpart of Crry/p65 from the struc- 
tural and functional similarities. Thus in rats, it is likely that 
a single molecule, the 512Ag, subserves the functions of  both 
DAF and MCP in humans. Suppression of this molecule thus 
dramatically reduces control at the C3 convertase stage, in- 
ducing severe disease through complement activation on the 
vascular endothelium. 
Finally, it was shown that suppression of rat CD59 by a mAb 6D1 induced decrease of hematocrit and erythrocyte 
concentration in vivo. Since direct evidences showing intravas- 
cular hemolysis such as increase of plasma LDH or free he- 
moglobin level (detected by absorbance at 0D414) were not 
demonstrable in the present study, the precise mechanism is 
currently unknown. Further studies are needed to solve the 
problem. 
In conclusion, mAb 512, induced the biphasic change in 
mean arterial pressure.  The effects of 512 on blood pressure 
were complement-dependent and due to the functional sup- 
pression  of a complement regulatory protein (SI2Ag,  a rat 
counter part  of mouse Crry/p65)  present  on vascular  en- 
dothelial cells and the subsequent activation of complement 
on the endothelial surface. In contrast, suppression of CD59, 
an inhibitor of the terminal complement pathway, did not 
render the cells susceptible  to complement attack and had 
no effect on blood pressure. Nevertheless, it is likely that simul- 
taneous suppression  of both regulators will enhance comple- 
ment-mediated damage in vivo. These studies are currently 
in progress.  Since there has been no report concerning the 
effects of functional suppression  of cell membrane-associated 
complement regulatory proteins in vivo, we believe that the 
findings presented here give new insights into the roles of 
membrane complement regulatory molecules in suppressing 
complement activation in vivo and in maintaining homeostasis. 
The authors thank N. Suzuki, N. Kuno, M. Miyawaki, M. Hagino, and M. Kumagai for their excellent 
technical assistance. We also thank Drs. H. Kawahara, C. Yamazaki, A. Ito, T. Toriyama,  and M. Mizuno 
for their technical help, suggestion, and continuous encouragement. 
This work was supported by 1992 research grants from Nagoya Kyouritsu Hospital and Masuko Memorial 
Hospital (Nagoya,  Japan). This work was also supported by a grant from The Mochida Foundation. B. P. 
Morgan is a Wellcome Senior Research Fellow. 
Address correspondence to Dr. Hidechika  Okada, Department of  Molecular Biology,  Nagoya  City University 
School of Medicine, Mizuho-cho, Mizuho-ku,  Nagoya 467, Japan. 
Received for publication 24January  1994 and in revised  form 30June  I994. 
References 
1.  Hourcade,  D., V.M. Holers, andJ.P. Atkinson. 1989. The regu- 
lators of complement activation (RCA) gene cluster. Adv. Im- 
munol. 45:381. 
2.  Nicholson-Weller, A.,  J.  Burge, and  K.F. Austen.  1981. 
Purification from guinea pig erythrocyte stroma of a decay- 
accelerating factor for the classical C3 convertase, C4b,2a.  J. 
ImmunoL 127:2035. 
3.  Nicholson-Weller,  A., J. Burge, D.T. Fearon, P.F. Weller, and 
K.F. Austen. 1982. Isolation of a human erythrocyte mem- 
brane glycoprotein  with decay-accelerating  activity for C3 con- 
vertases of the complement system. J. Immunol. 129:184. 
4.  Ballard, L.L., T. Seya,  J. Teckman, D.M. Lublin, andJ.P. At- 
kinson. 1987. A polymorphism of the complement regulatory 
protein MCP (membrane cofactor protein or gp45-70). J. Im- 
munoL 138:3850. 
5.  Ballard, L.L., N.S. Bora, G.H. Yu, and J.P. Atkinson. 1988. 
Biochemical  characterization of membrane cofactor protein of 
the complement system. J. Immunol. 141:3923. 
6.  Seya,  T., L. BaUard, N. Bora, T. McNearney,  andJ.P. Atkinson. 
1988. Distribution  of membrane cofactor protein (MCP) of 
complement on human peripheral blood cells. Eur.J. Immunol. 
18:1289. 
7.  Lublin, D.M.,  and J.P. Atkinson.  1989. Decay-accelerating 
factor and membrane cofactor protein. Cura. Top. Microbial. Im- 
munol. 153:123. 
8.  Okada,  N., R. Harada, T. Fujita, and H. Okada. 1989. A novel 
membrane glycoprotein capable of inhibiting membrane at- 
tack by homologous complement. Int. Immunol. 1:205. 
9.  Nicholson-Weller, A., J.P. March, S.I. Rosenfeld, and K.F. 
Austen. 1983. Affected erythrocytes of patients with parox- 
ysmal nocturnal hemoglobinuria are deficient in the comple- 
ment regulatory protein, decay accelerating factor. Proc. Natl. 
Acad. Sci. USA.  80:5066. 
10.  Pangburn, M.K., R.D. Schreiber, and H.J. Mtiller-Eberhard. 
1983. Deficiency of an erythrocyte membrane protein with 
complement regulatory activity  in paroxysmal  nocturnal hemo- 
globinuria. Proc. Natl. Acad. Sci. USA.  80:5430. 
11.  Kameyoshi,  Y., M. Matsushita, and H. Okada. 1989. Murine 
membrane inhibitor of complement which accelerates decay 
of human C3 convertase. Immunology. 68:439. 
12.  Paul, M.S., M. Aegerter, K. Cepek, M.D. Miller, and J.H. 
Weis. 1990. The murine complement receptor gene family.  III. 
The genomic and transcriptional complexity of the Crry and 
Crry-ps genes.  J. ImmunoL 144:1988. 
13. Wong, W.W., and D.T. Fearon. 1985. p65: a C3b-binding pro- 
tein in murine cells that shares antigenic determinants with 
the human C3b receptor (CR1) and is distinct from murine 
C3b receptor, j. Immunol. 134:4048. 
14.  Foley,  S., B. Li, M. Dehoff, H. Molina, and V.M. Holers. Mouse 
Crry/p65 is a regulator of the alternative pathway of comple- 
ment activation. Eur. J. Immunol. 23:1381. 
15.  Li, B., C. Sallee, M. Dehoff, S. Foley, H. Molina, and V.M. 
Holers. 1993. Characterization of monoclonal antibodies and 
the tissue distribution of a functional homologue of human 
MCP and DAF. J. Immunol. 151:4295. 
16.  Takizawa,  H., N. Okada, and H. Okada. 1994. Complement 
inhibitor of rat cell membrane resembling mouse Crry/p65. 
J. Immunol. 152:3032. 
1626  In Vivo Effects of Antibodies to Rat Complement Regulatory  Proteins 17.  Funabashi,  K.,  N.  Okada,  S.  Matsuo,  T.  Yamamoto, B.P. 
Morgan, and H. Okada. 1994. Tissue distribution of comple- 
ment regulatory membrane proteins in rats. Immunology. 81:444. 
18.  Sakurada, C., H. Seno, N. Dohi, H. Takizawa, M. Nonaka, 
N. Okada, and H. Okada. 1994. Molecular cloning of the rat 
complement regulatory protein, 512 antigen. Biochem. Biophys. 
Res. Commun.  198:819. 
19.  Hughes, T.R., S.J. Piddlesden, J.D. Williams, R.A. Harrison, 
and B.P. Morgan. 1992. Isolation  and characterization  of a mem- 
brane protein from rat erythrocytes which inhibits lysis  by the 
membrane  attack  complex  of rat complement.  Biochem. J. 
284:169. 
20.  Lachmann, P.J., L. Halbwachs, A. Gewurz, and H. Gewurz. 
1976. Purification of cobra venom factor from phospholipase 
A contaminant.  Immunology. 31:961. 
21.  Huey, R., C.M. Bloor, M.S. Kawahara, and T.E. Hugli. 1983. 
Potentiation of the anphylatoxins in vivo using an inhibitor 
of serum carboxypeptidase N (SCPN). I. Lethality and patho- 
logic effects on pulmonary  tissue. Am. J. Pathol. 112:48. 
22.  Matsuo, S., F. Yoshida, Y. Yuzawa, S. Hara, A. Fukatsu, Y. 
Watanabe, and N. Sakamoto. 1989. Experimental glomerulo- 
nephritis induced in rats by a lectin and its antibodies. Kidney 
Int.  36:1011. 
23.  Ozaki,  I.,  Y.  Ito,  A.  Fukatsu,  N.  Suzuki,  F.  Yoshida, Y. 
Watanahe, N. Sakamoto, and S. Matsuo. 1990. A plasma mem- 
brane antigen of rat glomerular epithelial cells. Antigenic de- 
terminants involving  N-linked sugar residues in a 140 kilodalton 
sialoglycoprotein of the podocytes. La/~ Invest. 63:707. 
24.  Platt, J., and A.F. Michael. 1983. Retardation  of fading and 
enhancement of intensity of immunofluorescence by p-phen- 
ylene-diamine. J. Histochem. Cytochem. 31:840. 
25.  Damerau, B. 1987. Biological  activities of  complement-derived 
peptides. Rev. Physiol. Biochem. Pharmacol. 108:152. 
26.  Wedmore, C.V,, and T.J. Williams. 1981. Control of vascular 
permeability by polymorphonuclear leukocytes in inflamma- 
tion. Nature (Lond.). 289:646. 
27.  From, A.H.L., H. Gewurz, R.P. Gruninger, R.J. Picketing, 
and W374. Spink. 1970. Complement in endotoxin shock: effect 
of complement depletion on the early hypotensive phase. In- 
fect. Immun.  2:38. 
28.  Godsoe, A., R. Kimura, D. Herndon, J.T. Flynn, G. Schlag, 
L. Traber, and D. Traber. 1988. Cardiopulmonary changes with 
intermittent endotoxin administration  in sheep. Circ. Shock. 
25:61. 
29.  Smedeg~rd, G., L.  Cui, and T.E. Hugli.  1989. Endotoxin- 
induced shock in the rat; a role for CSa. Am.J. Pathol. 135:489. 
30.  Lundberg, C., F. Marceau, and T.E. Hugli. 1987. C5a-induced 
hemodynamic and hematologic changes in the rabbit. Am. J. 
Pathol. 128:471. 
31.  Ulevitch,  R.J.,  and  C.G. Cochrane.  1977. Complement- 
dependent hemodynamic and hematologic change in the rabbit. 
Inflammation. 2:199. 
32.  Vogt, W. 1986. Anaphylatoxins: possible  roles in disease. Com. 
plement. 3:177. 
33.  McNearney, T., L. Ballard, T. Seya, and J.P. Atkinson.  1989. 
Membrane cofactor  protein of  complement is present on human 
fibroblast, epithelial, and endothelial  cells.J. Clin. Invest. 84:538. 
1627  Matsuo  et al. 